Because CD20 is a biomarker of DLBCL (Fig. S2B) and detected in plasma exosomes (Fig. S2C, Supplementary file 5), we regarded CD20 + exosomes as DLBCL-derived exosomes and CCDC50 + exosomes out of CD20 + exosomes as DLBCL-derived CCDC50 + exosomes. Here, CCDC50 is linked to diffuse large B-cell lymphoma.